RECURRENT TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Clinical trials for RECURRENT TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RECURRENT TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double-Punch trial aims to tame aggressive blood cancer
Disease control Recruiting nowThis study is testing whether combining two targeted cancer drugs is safe and effective for patients with an aggressive type of lymphoma that has come back or stopped responding to other treatments. The two drugs work together: one delivers a toxin directly to cancer cells, while…
Matched conditions: RECURRENT TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Mar 31, 2026 12:12 UTC
-
New bridge therapy aims to get more patients to lifesaving CAR-T treatment
Disease control Recruiting nowThis study is testing a drug called odronextamab to see if it can help control aggressive lymphoma long enough for patients to receive CAR-T cell therapy, a potentially curative treatment. The drug is given before the process to collect immune cells for CAR-T begins, with the goa…
Matched conditions: RECURRENT TRANSFORMED INDOLENT B-CELL NON-HODGKIN LYMPHOMA TO DIFFUSE LARGE B-CELL LYMPHOMA
Phase: PHASE2 • Sponsor: University of Washington • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC